---
category: trading
circular_id: 662f9c07f14e87a3
date: '2025-12-30'
description: 'BSE revokes the suspension of trading in equity shares of Rekvina Laboratories
  Limited (Scrip Code: 526075), allowing normal trading to resume.'
draft: false
guid: https://www.bseindia.com/markets/MarketInfo/DispNoticesNCirculars.aspx?Noticeid={F3349061-F124-4E89-A312-EFE0B6AC1B6C}&noticeno=20251230-9&dt=12/30/2025&icount=9&totcount=13&flag=0
impact: medium
impact_ranking: medium
importance_ranking: medium
justification: Revocation of trading suspension for a single company allows shareholders
  to resume trading but has limited broader market impact
pdf_url: https://www.bseindia.com/markets/MarketInfo/DownloadAttach.aspx?id=20251230-9&attachedId=87682fdc-cc89-475e-a9de-1cb2933a1fdd
processing:
  attempts: 1
  content_hash: ab900596948c5733
  processed_at: '2025-12-30T09:29:00.134866'
  processor_version: '2.0'
  stage: completed
  status: published
published_date: '2025-12-30T07:36:30+00:00'
rss_url: https://www.bseindia.com/markets/MarketInfo/DispNoticesNCirculars.aspx?Noticeid={F3349061-F124-4E89-A312-EFE0B6AC1B6C}&noticeno=20251230-9&dt=12/30/2025&icount=9&totcount=13&flag=0
severity: medium
source: bse
stocks:
- REKVINA
tags:
- trading-suspension-revocation
- equity-shares
- rekvina-laboratories
- pharmaceutical
- waghodia-gidc
title: Revocation of Suspension in Trading of Rekvina Laboratories Ltd.
---

## Summary

BSE has revoked the suspension of trading in equity shares of Rekvina Laboratories Limited (Scrip Code: 526075, ISIN: INE092O01028). The company, a pharmaceutical manufacturer focused on providing quality medication at affordable prices, is now permitted to resume normal trading activities on the Bombay Stock Exchange.

## Key Points

- Company Name: Rekvina Laboratories Limited
- Scrip Code: 526075
- ISIN: INE092O01028
- Trading suspension has been revoked
- Company operates in the pharmaceutical industry
- Manufacturing facility located at GIDC Estate, Waghodia, Vadodara-391760
- Registered office: 36-Sampatrao Colony, Alkapuri, Vadodara-390007
- Managing Director: Amit Mukesh Shah (DIN: 01993211)
- Company Secretary: Deepak Khandelwal
- Current Auditor: M/s. Y.M. Shah & Co. (FRN: 114124W) for 2024-25 to 2028-29
- Group Company: Radiant Parenterals Limited
- Operational Status: Active

## Company Profile

**Business Nature**: Pharmaceutical industry focused on providing quality medication at affordable prices to help reduce healthcare costs

**Board of Directors**:
- Amit Mukesh Shah (Managing Director & Chairman)
- Surbhit Mukesh Shah
- Dhruvalkumar Patel
- Chetanbhai Patel
- Ilaben Pathak
- Parteek Jain

**Auditor Changes**: The company changed auditors from M/s. Jigar Adhyaru & Co. (2019-20 to 2023-24) to M/s. Y.M. Shah & Co. (2024-25 to 2028-29) due to completion of statutory term by the previous auditor in compliance with regulatory requirements.

## Regulatory Changes

Trading suspension previously imposed on Rekvina Laboratories Limited has been lifted, restoring normal trading status for the company's equity shares on BSE.

## Compliance Requirements

- Company has confirmed payment of listing fees to BSE
- Company maintains active operational status
- No action taken by other exchanges in the last five years
- Company website: https://rekvinalaboratories.in/

## Important Dates

- Circular Date: December 30, 2025
- Effective Date: Trading suspension revoked as of this circular

## Impact Assessment

**Market Impact**: Medium - The revocation allows shareholders of Rekvina Laboratories to resume trading their equity holdings. This is positive for existing shareholders who were unable to trade during the suspension period.

**Operational Impact**: Positive for the company as it restores market confidence and provides liquidity to shareholders. The company continues active pharmaceutical manufacturing operations at its Waghodia facility.

**Investor Impact**: Shareholders can now buy, sell, or trade equity shares of Rekvina Laboratories on BSE, restoring market liquidity for this security.